Abstract
Tumor necrosis factor-α (TNFα) has been implicated in cancer and inflammatory diseases since it was first characterized and eventually identified by researchers in several laboratories in the mid-1980s [1-5]. However, only recently has the patho-logical role of TNF in arthritis and Crohn’s disease been demonstrated in the clinic with the FDA’s approval of Enbrel and Remicade [6-8]. The recent success of these biological agents that neutralize TNF has led to intense efforts to find small molecule TNF antagonists that will mimic the consequences, if not the mechanism, of these agents. Because TNF interacts at multiple contact points with either of its two receptors, researchers have struggled to find small molecular weight inhibitors that antagonize this interaction. Therefore, most efforts have focused on targets upstream of TNF synthesis or secretion and downstream of TNF receptor engagement since these targets appear more amenable to modulation by small molecular weight inhibitors [9].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Beutler B, Mahoney J, Nguyen LT, Pekala P, Cerami A (1985) Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med 161: 984–995
Haranaka K, Carswell EA, Williamson BD, Prendergast JS, Satomi N, Old LJ (1986)Purification, characterization, and antitumor activity of non-recombinant mouse tumor necrosis factor. Proc Natl Acad Sci USA 83: 3949–3953
Aggarwal BB, Kohr WJ, Hass PE, Moffat B, Spencer SA, Henzel WJ, Bringman TS, Nedwin GE, Goeddel DV, Harkins RN (1985) Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem 260: 2345–2354
Pennica D, Hayflick JS, Bringman TS, Palladino MA, Goeddel DV (1985) Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor. Proc Natl Acad Sci USA 82: 6060–6064
Wang, AM, Creasey AA, Ladner MB, Lin LS, Strickler J, Van Arsdell JN, Yamamoto R, Mark DF (1985) Molecular cloning of the complementary DNA for human tumor necrosis factor. Science 228: 149–154
Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K et al (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337: 141–147
Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340: 253–259
Targan SR, Hanauer S., Van Deventer SJH, Mayer L, Present DH, Braakman T, Dewoody KL, Schaible TF, Rutgeerts PJ (1997) A short-term study of chimeric mono-clonal antibody cA2 to tumor necrosis factor a for Crohn’s disease. N Engl J Med 337: 1029–1035
Shire MG, Muller GW (1998) TNF-a inhibitors and rheumatoid arthritis. Expert Opin Ther Pat8: 531–544
Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russell WE, Cast-ner BJ, Johnson RS, Fitzner JN et al (1998) An essential role for ectodomain shedding in mammalian development. Science 282: 1281–1284
McGeehan GM, Becherer JD, Bast RC, Boyer CM, Champion B, Connolly K, Conway J, Furdon P, Karp S, Kidao S et al (1994) Regulation of tumor necrosis factor-a processing by a metalloproteinase inhibitor. Nature 370: 558–561
Mohler KM, Sleath PR, Fitzner JN, Cerretti DP, Alderson M, Kerwar SS, Torrance DS, Otten-Evans C, Greenstreet T, Black RA (1994) Protection against a lethal dose of endotoxin by an inhibitor of tumor necrosis factor processing. Nature 370: 218–221
Gearing AJH, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R (1994) Processing of tumor necrosis factor-a precursor by metalloproteases. Nature 370: 555–558
Moss ML, Jin SC, Mulla ME, Burkhart W, Carter HL, Chen W., Clay WC, Didsbury JR, Hassler D, Hoffman CR et al (1997) Cloning of a disintegrin metalloproteinase that processes precursor tumor necrosis factor-a. Nature 385: 733–736
Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srunivasan S et al (1997) A metalloproteinase disintegrin that releases tumor necrosis factor-a from cells. Nature 385: 729–733
Hooper NM (1994) Families of zinc metalloproteases. FEBS Lett 354: 1–6
Blobel CP (1997) Metalloprotease-disintegrins: links to cell adhesion and cleavage of TNF-a and Notch. Cell 90: 589–592
Hooper NM, Karran EH, Turner AJ (1997) Membrane protein secretases. Biochem J 321: 265–279
Black RA, White JM (1998) ADAMs: focus on the protease domain. Curr Opin Cell Biol 10: 654–659
Brown AM, George SM, Blume AJ, Dushin RG, Jacobsen JS, Sonnenberg-Reines J (1994) Biotinylated and cysteine-modified peptides as useful reagents for studying the inhibition of cathepsin G. Anal Biochem 217: 139–147
Basak A, Boudreault A, Jean F, Chretien M, Lazure C (1993) Radiolabeled biotinyl peptides as useful reagents for the study of proteolytic enzymes. Anal Biochem 209 (2): 306–314
Baum EZ, Hohnston SH, Bebernitz GA, Gluzman Y (1996) Development of a scintillation proximity assay for human cytomegalovirus protease using 33Phosphorus. Anal Biochem 237: 129–134
Cook ND, Jessop RA, Robinson PS, Richards AD, Kay J (1991) Structure and function of the aspartic proteinases. In: BM Dunn (ed): Scintillation proximity enzyme assay: a rapid and novel assay technique applied to HIV proteinase. Plenum Press, London, 525–528
Jones AE, Saksela K, Game SM, O’Beirne G, Cook ND (1998) Screening assay for the detection of the protein-protein interaction between HIV-1 Nef protein and SH3 domain of Hck. J Biomolec Screening 3 (1): 37–41
Pernelle C, Clerc FF, Dureuil C, Bracco L, Tocque B (1993) An efficient screening assay for the rapid and precise determination of affinities between leucine zipper domains. Biochemistry 32 (43): 11682–11687
Nelson N (1987) A novel method for the detection of receptors and membrane proteins by scintillation proximity radioassay. Anal Biochem 165: 287–293
Nichols JS, Parks DJ, Consler TG, Blanchard SG (1998) Development of a scintillation proximity assay for peroxisome proliferator-activated receptor gamma ligand binding domain. Anal Biochem 257: 112–119
Cook ND (1996) Scintillation proximity assay: A versatile high-throughput screening technology. Drug Discovery Today 1 (7): 287–294
Ziegler-Heitbrook HWL, Thiel E, Fuetter A, Herzog V, Wirtz A, Reithmueller G (1988) Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int J Cancer 41: 456–461
Van Dyk DE, Marchand P, Bruckner RC, Fox JW., Jaffee BD, Gunyuzlu PL, Davis GL, Nurnberg S, Covington M, Decicco CP et al (1997) Comparison of snake venom reprolysin and matrix metalloproteinases as models of TNF-a converting enzyme. Bioorg Med Chem Lett 7:1219–1224
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Basel AG
About this chapter
Cite this chapter
Leesnitzer, M.A., Bickett, D.M., Moss, M.L., Becherer, J.D. (2000). A high throughput assay for the TNF converting enzyme. In: Kahn, M. (eds) High Throughput Screening for Novel Anti-Inflammatories. Progress in Inflammation Research. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8462-4_5
Download citation
DOI: https://doi.org/10.1007/978-3-0348-8462-4_5
Publisher Name: Birkhäuser, Basel
Print ISBN: 978-3-0348-9578-1
Online ISBN: 978-3-0348-8462-4
eBook Packages: Springer Book Archive